P2RY12 and myocardial infarction: In this systematic review and meta-analysis of 7 randomized clinical trials with 13 226 patients, oral P2Y12 pretreatment was associated with no difference in 30-day cardiovascular events, myocardial infarction, or cardiovascular death, but it was associated with an increased risk of bleeding.